Precompetitive research models have evolved from industry-academic collaborations to multi-stakeholder, cross-continental endeavors. This panel will explore the benefits recent open innovation alliances are providing their members and how to get involved. Speakers will describe the EU’s largest public-private effort to speed delivery of new medicines and the role of engagement from regulators; discuss what AstraZeneca has learned from collaborations with the NIH National Center for the Advancement of Translational Sciences and “declassifying” information about its compounds; and explain why Asian academic and government groups are ideally suited to open innovation and how Western companies should approach new Asian partners.
- Discuss the growing trend toward multi-stakeholder, global biopharma research collaborations
- Describe ways that ground-breaking open innovation efforts are delivering benefits and supporting the next wave of precompetitive collaboration
- Emphasize that it is not too late to capitalize on open innovation opportunities
Ability Level: All
Session ID: 2501